KROS

Keros Therapeutics Inc

9.45

Nov 05 • 3:59 PM ET -1.38 (-12.74%)

9.45

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Today, 6:16 PMKeros Therapeutics Inc reports fiscal Q3 2026 results with non-GAAP EPS $0.70 (+489% YoY) and revenue $40.0M (+181% YoY), beats EPS and revenue estimates

Peers: SRRK CAPR EWTX TRDA SLDB DYN SRPT WVE GERN IRON

| Held by: VTI IWM VXF IWN DFSV IBB VTWO SMLF BSVO SCHA

Scroll to Statements

Index	RUT
Market Cap	187.37M
Enterprise Value	-54.52M
Income	-83.16M
Sales	15.01M
Book/sh	13.23
Cash/sh	12.99
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	78
IPO	Apr 08, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	12.48
P/B	0.71
P/C	0.73
P/FCF	-
EV/EBITDA	-
EV/Sales	-3.63
Quick Ratio	21.96
Current Ratio	21.96
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-3.70
EPS next Y	-6.24
EPS next Q	-1.93
EPS this Y	-340.77%
EPS next Y	-12.61%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-1143.58%
Sales Y/Y TTM	-93.55%
EPS Q/Q	-91.85%
Sales Q/Q	-100.00%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	174.53% 170.98%

Insider Own	8.45%
Insider Trans	-0.84%
Inst Own	92.36%
Inst Trans	-1.92%
ROA	-15.92%
ROE	-17.16%
ROIC	-30.19%
Gross Margin	89.34%
Oper. Margin	-675.27%
Profit Margin	-553.88%
SMA20	-15.06%
SMA50	-15.75%
SMA200	-20.55%
Trades

Shs Outstand	19.83M
Shs Float	18.15M
Short Float	6.26%
Short Ratio	6.15
Short Interest	1.14M
52W High	22.55 -58.09%
52W Low	9.69 -2.48%
Volatility	7.42% 5.30%
ATR (14)	0.59
RSI (14)	28.45
Beta	1.19
Rel Volume	1.29
Avg Volume	184.93K
Volume	238,441

Perf Week	-16.81%
Perf Month	-15.70%
Perf Quarter	-15.25%
Perf Half Y	-18.81%
Perf YTD	-53.59%
Perf Year	-39.62%
Perf 3Y	-70.41%
Perf 5Y	-83.04%
Perf 10Y	-
Recom	1.86
Target Price	19.83
Prev Close	10.83
Price	9.45
Change %	-12.74%

Consensus

Buy

Avg. Price Target

$19.83

Implied Upside

+109.8%

Analysts13incl. previous ratings

Rating Distribution6 Buy · 7 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 20, 2025	Initiated	WWells Fargo	Overweight	$26	+175.1%
Jun 10, 2025	Downgrade	BBofA Securities	Buy → Neutral	$18	+90.5%
Jan 21, 2025	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Jan 17, 2025	Downgrade	WWedbush	Outperform → Neutral	$15	+58.7%
Dec 16, 2024	Reiterated	OOppenheimer	Outperform	$102 → $63	+566.7%
Dec 16, 2024	Downgrade	GGuggenheim	Buy → Neutral
Dec 13, 2024	Reiterated	HH.C. Wainwright	Buy	$100 → $47	+397.4%
Dec 12, 2024	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Dec 12, 2024	Downgrade	TTD Cowen	Buy → Hold
Dec 12, 2024	Downgrade	BBTIG Research	Buy → Neutral
Nov 05, 2024	Initiated	JJefferies	Buy
Oct 24, 2024	Initiated	CCantor Fitzgerald	Overweight
Oct 16, 2024	Initiated	BScotiabank	Sector Outperform
Sep 23, 2024	Initiated	GGuggenheim	Buy	$96	+915.9%
Jun 25, 2024	Initiated	OOppenheimer	Outperform	$102	+979.4%
Feb 21, 2024	Initiated	WWilliam Blair	Outperform
Dec 08, 2023	Initiated	WWells Fargo	Overweight	$60	+534.9%
Jul 31, 2023	Initiated	WWedbush	Outperform	$86	+810.1%
Jul 26, 2023	Initiated	BBofA Securities	Buy	$65	+587.8%
Feb 14, 2023	Initiated	CCowen	Outperform

Today 04:01PM	Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2026 Financial Results (GlobeNewswire) -12.74%
Oct-20-26 08:59AM	A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday (PR Newswire)
Sep-29-26 08:00AM	Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda (GlobeNewswire)
Sep-28-26 08:00AM	Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD (GlobeNewswire)
Sep-08-26 04:01PM	Keros Therapeutics Announces $5 Million Share Repurchase Authorization (GlobeNewswire)
04:01PM	Loading…
Aug-03-26 04:01PM	Keros Therapeutics Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-30-26 04:01PM	Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda (GlobeNewswire)
Jun-25-26 04:01PM	Keros Therapeutics Appoints Anne Prener to its Board of Directors (GlobeNewswire) +5.57%
Jun-01-26 04:01PM	Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-14-26 08:00AM	Keros Therapeutics Reports Recent First Quarter 2026 Financial Results (GlobeNewswire) -8.34%
Mar-09-26 08:00AM	Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference (GlobeNewswire)
08:00AM	Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS (GlobeNewswire)
Mar-06-26 11:57AM	Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? (Zacks)
Mar-05-26 12:53PM	Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? (Zacks) -14.96%
Mar-04-26 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-28-26 12:35PM	Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference (MarketBeat)
Feb-26-26 04:01PM	Keros Therapeutics Appoints Charles Newton to its Board of Directors (GlobeNewswire) -5.59%
Feb-18-26 04:01PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
09:39AM	Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? (Zacks)
Feb-03-26 11:39AM	Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results? (Zacks)
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-26-26 09:15AM	Is KROS' KER-065 the Next Breakthrough in DMD Space? (Zacks)
Jan-23-26 07:18AM	JANX Enters Global Oncology Collaboration With BMY, Stock Rises (Zacks)
Jan-22-26 11:55AM	Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema (Zacks)
Jan-21-26 08:36AM	MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know (Zacks)
Jan-19-26 12:53PM	Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease (Zacks)
Jan-16-26 11:15AM	Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia (Zacks)
09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
10:26AM	Loading…
Jan-15-26 10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
09:14AM	KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? (Zacks)
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-12-26 09:32AM	INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced (Zacks)
Jan-08-26 12:33PM	GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies (Zacks)
Jan-02-26 12:41PM	This Health Name Gains Over 400% In 2025. A Gold Stock Is Right Behind It. (Investor's Business Daily) -8.94%
04:32AM	Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics (Zacks)
Dec-31-25 07:33AM	5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close (Zacks)
Dec-30-25 11:40AM	KROS or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Dec-22-25 12:00PM	Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why (Zacks) +5.33%
09:55AM	Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher (Zacks)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
04:02AM	Zacks.com featured highlights include StoneCo, General Motors, Enersys, Deutsche, Keros (Zacks)
Dec-15-25 09:14AM	Buy These 5 Best Value Stocks to Boost Your Portfolio in December (Zacks)
Dec-12-25 12:00PM	What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now? (Zacks)
11:40AM	KROS vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
Nov-28-25 09:53AM	Buy These 5 Best Value Stocks to Make the Most of P/B Ratio (Zacks)
Nov-26-25 11:40AM	KROS or NVZMY: Which Is the Better Value Stock Right Now? (Zacks)
09:55AM	How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% (Zacks)
Nov-20-25 04:01PM	Keros Therapeutics Announces Final Results of Tender Offer (GlobeNewswire)
Nov-19-25 06:00AM	Keros Therapeutics Announces Preliminary Results of Tender Offer (GlobeNewswire)
Nov-13-25 07:34AM	5 Undervalued Stocks That Are Poised for Growth in November (Zacks)
Nov-10-25 11:40AM	KROS vs. ARGX: Which Stock Is the Better Value Option? (Zacks) +5.19%
09:55AM	Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? (Zacks)
Nov-05-25 05:40PM	Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-21-25 09:43AM	Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? (Zacks)
Oct-20-25 06:00AM	Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares (GlobeNewswire) +9.83%
Oct-15-25 06:30AM	Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital (GlobeNewswire)
Sep-08-25 08:00AM	Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting (GlobeNewswire)
Aug-28-25 04:01PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Aug-21-25 08:30AM	ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment (PR Newswire) +6.61%
06:56AM	Keros gains FDA orphan drug status for DMD treatment KER-065 (Pharmaceutical Technology)
Aug-20-25 09:48AM	Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-06-25 05:45PM	Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -7.29%
04:15PM	Keros to Exclusively Prioritize the Clinical Advancement of KER-065 (GlobeNewswire)
04:01PM	Keros Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-28-25 11:40AM	KROS vs. EXAS: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-23-25 10:54AM	Will Reblozyl Enable BMY to Offset the Impact of Generic Competition? (Zacks) +5.10%
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks)
10:39AM	FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo (Zacks)
Jul-17-25 08:00AM	Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept (GlobeNewswire)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
Jun-11-25 09:40AM	McDonalds downgraded on GLP-1 drug worries: Wall Streets top analyst calls (TipRanks)
Jun-10-25 02:37PM	Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst (Benzinga)
Jun-09-25 03:12PM	ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal (PR Newswire) -6.32%
06:55AM	Keros Announces Return of $375 Million in Excess Capital to Stockholders (GlobeNewswire)
Jun-06-25 04:01PM	Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-30-25 06:36AM	Keros lays off nearly half its staff; Astellas buys into a China biotechs ADC (BioPharma Dive)
May-29-25 11:24PM	Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial (Insider Monkey)
12:54PM	Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% (Benzinga)
06:55AM	Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring (GlobeNewswire)
May-27-25 01:45PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees (GlobeNewswire)
May-21-25 08:00AM	ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
May-19-25 08:00AM	Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value (GlobeNewswire)
May-12-25 12:11PM	ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
08:00AM	Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference (GlobeNewswire)
May-08-25 05:31PM	Keros Reinforces Commitment to Maximizing Stockholder Value (GlobeNewswire)
02:10PM	ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders (PR Newswire)
May-06-25 07:10PM	Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates (Zacks) -5.46%
04:01PM	Keros Therapeutics Reports Recent First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-02-25 08:40AM	Implied Volatility Surging for Keros Therapeutics Stock Options (Zacks)
Apr-11-25 02:13PM	Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation (Seeking Alpha)
12:05PM	Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz (TipRanks)
11:57AM	KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5% (Zacks)
Apr-10-25 12:58PM	Keros Therapeutics considers sale amid investor pressure (Pharmaceutical Technology) +18.49%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tanini Annita	Corp. Controller & VP, Finance	Aug 18 '26	Sale	10.29	1,224	12,595	45,144	Aug 20 04:10 PM
Lerner Lorena Raquel	Chief Scientific Officer	Aug 18 '26	Sale	10.29	3,568	36,715	27,559	Aug 20 04:10 PM
Cho Esther	Chief Legal Officer	Aug 18 '26	Sale	10.29	4,485	46,151	35,770	Aug 20 04:10 PM
Newton Charles W.	Director	Aug 18 '26	Sale	10.30	551	5,675	12,114	Aug 20 04:10 PM
BIENAIME JEAN JACQUES	Director	Aug 17 '26	Buy	10.27	1,000	10,270	19,592	Aug 19 04:10 PM
Newton Charles W.	Director	Aug 18 '26	Proposed Sale	10.38	551	5,719		Aug 18 04:11 PM
BIENAIME JEAN JACQUES	Director	Jul 15 '26	Buy	10.61	1,000	10,610	18,592	Jul 17 04:10 PM
BIENAIME JEAN JACQUES	Director	Jun 15 '26	Buy	10.19	1,000	10,190	17,592	Jun 17 04:55 PM
Newton Charles W.	Director	Jun 11 '26	Sale	10.04	550	5,522	12,665	Jun 15 04:15 PM
Newton Charles W.	Director	Jun 11 '26	Proposed Sale	9.95	550	5,472		Jun 11 04:15 PM
Farzan Nima	Director	Jun 04 '26	Sale	10.73	2,625	28,166	9,767	Jun 08 04:37 PM
Knowles Julius	Director	Jun 04 '26	Sale	10.73	2,625	28,166	10,958	Jun 08 04:36 PM
Seth Alpna	Director	Jun 04 '26	Sale	10.72	2,625	28,140	9,767	Jun 05 04:15 PM
Farzan Nima	Director	Jun 04 '26	Proposed Sale	10.68	2,625	28,035		Jun 04 04:11 PM
Knowles Julius	Director	Jun 04 '26	Proposed Sale	10.68	2,625	28,035		Jun 04 04:09 PM
Seth Alpna	Director	Jun 04 '26	Proposed Sale	10.68	2,625	28,035		Jun 04 04:07 PM
BIENAIME JEAN JACQUES	Director	May 15 '26	Buy	10.58	1,000	10,580	9,450	May 19 04:15 PM
BIENAIME JEAN JACQUES	Director	Apr 15 '26	Buy	11.70	1,000	11,700	8,450	Apr 17 04:15 PM
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Apr 02 '26	Option Exercise	0.30	55,000	16,500	440,708	Apr 06 04:15 PM
OrbiMed Genesis Master Fund, L	Shareholder	Mar 31 '26	Proposed Sale	11.04	45,057	497,429		Mar 31 09:57 PM
BIENAIME JEAN JACQUES	Director	Mar 09 '26	Buy	11.21	2,000	22,420	7,450	Mar 11 04:33 PM
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Feb 19 '26	Sale	16.17	7,015	113,433	385,708	Feb 20 04:15 PM
Lerner Lorena Raquel	Chief Science Officer	Feb 18 '26	Sale	16.35	3,873	63,324	31,127	Feb 20 04:15 PM
Cho Esther	SVP, General Counsel	Feb 18 '26	Sale	16.35	4,745	77,581	39,755	Feb 20 04:15 PM
Regnante Keith	CHIEF FINANCIAL OFFICER	Feb 18 '26	Sale	16.35	4,739	77,483	39,261	Feb 20 04:15 PM

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

PresidentDr. Jasbir S. Seehra Ph.D.

Chief Legal Officer & SecretaryMs. Esther Cho J.D.

VP of FinanceMs. Annita Tanini

Head of Investor RelationsJustin Frantz

Chief Scientific OfficerDr. Lorena Lerner Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KROS

Keros Therapeutics Inc

Upgrade your Finviz experience